Evidence map›Paper›PMID 40272699›Full record

ArticleClinical pharmacokinetics2025

Variability in Meropenem Distribution and Clearance in Children with Sepsis: Population-Based Pharmacokinetics with Assessment of Renal Biomarkers.

Jennifer Le, Julie Huynh, Brandon Vo, Annie Mai, Robert H Mak, Jeremiah D Momper, Edmund V Capparelli, Helen Harvey, Sean Avedissian, Erin Bradley and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacokinetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Correlation Between Renal Biomarkers, Glomerular Filtration Rate, and Meropenem Clearance in Pediatric Septic Shock.The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jennifer LeUniversity of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA. jel078@health.ucsd.edu.ORCID 0000-0002-6692-0884
Julie HuynhUniversity of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA.
Brandon VoUniversity of California Riverside, Riverside, CA, USA.
Annie MaiUniversity of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA.
Robert H MakSan Diego School of Medicine, University of California, La Jolla, CA, USA.
Jeremiah D MomperUniversity of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA.
Edmund V CapparelliUniversity of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, La Jolla, CA, USA.
Helen HarveyRady Children's Hospital, San Diego, CA, USA.
Sean AvedissianCollege of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA.
Erin BradleyRady Children's Hospital, San Diego, CA, USA.
Amy SitapatiSan Diego School of Medicine, University of California, La Jolla, CA, USA.
Karandeep SinghUniversity of California, San Diego Health, La Jolla, CA, USA.
John S BradleySan Diego School of Medicine, University of California, La Jolla, CA, USA. jbradley@rchsd.org.ORCID 0000-0002-3835-5064

Funding

Longitudinal Assessment of Beta-lactam Antibiotic Exposure in in Critically Ill Children with Sepsis in the PICU to Predict Dosing RequirementsR01HD095547 · NICHD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BRADLEY, JOHN S · 2018 to 2021
$2.4M
NICHD NIH HHS R01 HD095547
6 · The paper itself

Abstract

BACKGROUND AND

objectiveMeropenem dosing to achieve therapeutic exposure in critically ill children with sepsis is challenging due to a spectrum of renal function, from augmented renal clearance (ARC) to acute kidney injury (AKI). The objective of this study was to define meropenem plasma concentrations and pharmacodynamic exposure metrics in children with septic shock during the first 3 days of PICU hospitalization.

methodsWe prospectively evaluated meropenem clearance (CL

resultsAnalysis included 27 participants (19 cases and 8 controls) with 309 meropenem serum concentrations. Median age was 11.8 (range 0.6-19.6) years, weight 36.3 (7.2-98.0) kg, SCr 0.33 (0.09-2.57) mg/dL, SCys 451.1 (178.3-1824.1) ng/mL, and SNgal 180.7 (23.2-1403.0) ng/mL. A 2-compartment, population pharmacokinetic (PK) model via NONMEM best described data, with weight on V

conclusionWide variation in meropenem concentrations in children with sepsis as compared to those without sepsis prompt close monitoring of GFR and drug concentrations in this population.

Indexed as

Anti-Bacterial AgentsMeropenemSepsisAcute Kidney InjuryAdolescentBiomarkersChildChild, PreschoolCreatinineCystatin CFemaleGlomerular Filtration RateHumansInfantIntensive Care Units, PediatricKidneyAnti-Bacterial AgentsBiomarkersCreatinineCystatin CLipocalin-2Meropenem

Identifiers

PMID40272699
PMCPMC12064575

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.